Acute myeloid leukemia developed through myeloproliferative features during immunosuppressive therapy for juvenile idiopathic arthritis

Masahiro Oura,Ryohei Sumitani,Yusaku Maeda,Hikaru Yagi,Mamiko Takahashi,Takeshi Harada,Shiro Fujii,Hirokazu Miki,Taiki Hori,Jumpei Murai,Kumiko Kagawa,Masahiro Abe,Shingen Nakamura
DOI: https://doi.org/10.2152/jmi.71.335
Abstract:A 17-year-old male with thrombocytosis and exacerbation of arthralgia during intensified immunosuppressive therapy with tocilizumab, prednisolone, and methotrexate for juvenile idiopathic arthritis (JIA) was referred to our department. Bone marrow examination revealed myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U). Peripheral myeloblasts disappeared temporarily after discontinuation of tocilizumab but progressed to acute myeloid leukemia six months after the development of MDS/MPN-U. The patient sustained complete remission after unrelated bone marrow stem cell transplantation, followed by chemotherapy. The arthralgia also improved after chemotherapy. The possibility of developing malignancies during immunosuppressive therapy in patients with JIA should be considered. J. Med. Invest. 71 : 335-339, August, 2024.
What problem does this paper attempt to address?